# US 2010/0168018 A1 · Factor viii formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168018 A1
- Document ID: US20100168018A1
- Status: Published application
- Kind: A1
- Application number: 12/614,090
- Filed: 2009-11-06
- Published: 2010-07-01
- Earliest claimed: 2008-11-07
- Assignees: Baxter International Inc.; University of Connecticut
- Inventors: Michael Pikal; Serguei Tchessalov; Erik Bjornson; Feroz Jameel; Marc Besman
- Web page: https://patentgrep.com/patent/US20100168018A1

## CPC

- A61K 38/37: Factors VIII
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A Factor VIII (FVIII) composition formulated such that NaCl is not present in the final formulation or is present in trace amounts, which allows for a concomitant reduction in the lyophilization cycle time and increased stability of the lyophilized FVIII.

## Claims

### Claim 1

A stable lyophilized pharmaceutical formulation of Factor VIII (FVIII) comprising: (a) a FVIII; (b) one or more buffering agents; (c) one or more antioxidants; (d) one or more stabilizing agents; and (e) one or more surfactants;
said FVIII comprising a polypeptide selected from the group consisting of:
a) a recombinant FVIII polypeptide;
b) a biologically active analog, fragment or variant of a);
said buffer is comprising of a pH buffering agent in a range of about 0.1 mM to about 500 mM and said pH is in a range of about 2.0 to about 12.0;
said antioxidant is at a concentration of about 0.005 to about 1.0 mg/ml;
said stabilizing agent is at a concentration of about 0.005 to about 20%;
said surfactant is at a concentration of about 0.001% to about 1.0%; and
said formulation excluding sodium chloride (NaCl) or including only trace amount of NaCl.

### Claim 2 (depends on 1)

The formulation of claim 1 wherein the buffering agent is selected from the group consisting of citrate, glycine, histidine, HEPES, Tris and combinations of these agents.

### Claim 3 (depends on 2)

The formulation of claim 2 wherein the buffering agent is histidine.

### Claim 4 (depends on 1)

The formulation of claim 1 wherein pH is in the range of about 6.0 to about 8.0.

### Claim 5 (depends on 4)

The formulation of claim 4 wherein pH is in the range of about 6.5 to about 7.5.

### Claim 6 (depends on 1)

The formulation of claim 1 wherein the buffering agent is histidine and the pH is about 7.0.

### Claim 7 (depends on 1)

The formulation of claim 1 wherein the antioxidant is selected from the group consisting of glutathione.

### Claim 8 (depends on 7)

The formulation of claim 7 wherein the antioxidant is at a concentration range of about 0.1 to about 0.5 mg/ml.

### Claim 9 (depends on 8)

The formulation of claim 8 wherein the antioxidant is glutathione at a concentration of about 0.2 mg/ml.

### Claim 10 (depends on 1)

The formulation of claim 1 wherein the buffering agent is histidine and the pH is about 7.0; and wherein the antioxidant is glutathione at a concentration of about 0.2 mg/ml.

### Claim 11 (depends on 1)

The formulation of claim 1 wherein the one or more stabilizing agents is selected from the group consisting of sucrose, trehalose, and raffinose, and combinations of these stabilizing agents.

### Claim 12 (depends on 11)

The formulation of claim 11 wherein the stabilizing agents are trehalose at a concentration of about 5% and calcium chloride at a concentration of about 4 mM.

### Claim 13 (depends on 11)

The formulation of claim 11 wherein the stabilizing agents are sucrose at a concentration of about 5% and calcium chloride at a concentration of about 4 mM.

### Claim 14 (depends on 1)

The formulation of claim 1 wherein the surfactant is selected from the group consisting of digitonin, Triton X-100, Triton X-114, TWEEN-20, TWEEN-80 and combinations of these surfactants.

### Claim 15 (depends on 16)

The formulation of claim 16 wherein the surfactant is TWEEN-80 at about 0.03%.

### Claim 16 (depends on 1)

The formulation of claim 1 wherein the buffering agent is histidine at a concentration of about 25 mM at about pH 7.0; wherein the antioxidant is glutathione at a concentration of about 0.2 mg/ml; wherein the stabilizing agents are trehalose or sucrose at a concentration of about 5% and calcium chloride at a concentration of about 4 mM; and wherein the surfactant is TWEEN-80 at about 0.03%.

### Claim 17 (depends on 1)

The formulation of claim 1 wherein NaCl is not added as an excipient.

### Claim 18 (depends on 1)

The formulation of claim 1 wherein the sodium chloride is present in trace amount following removal by dialysis or solvent exchange chromatography.

### Claim 19 (depends on 1)

A method of preparing a stable, lyophilized FVIIII comprising the steps of
(a) preparing the formulation according to claim 1; and
(b) lyophilizing the formulation of step (a).

### Claim 20 (depends on 19)

The method according to claim 19 wherein stability of the lyophilized FVIII is higher compared to a FVIII formulation that is lyophilized in the presence of NaCl.

### Claim 21

A stable lyophilized pharmaceutical formulation of Factor VIII (FVIII) comprising: (a) a FVIII; (b) one or more buffering agents; (c) one or more antioxidants; (d) one or more stabilizing agents; and (e) one or more surfactants;
said FVIII comprising a polypeptide selected from the group consisting of:
a) a recombinant FVIII polypeptide;
b) a biologically active analog, fragment or variant of a);
said buffer is comprising of a pH buffering agent in a range of about 0.1 mM to about 500 mM and said pH is in a range of about 2.0 to about 12.0;
said antioxidant is at a concentration of about 0.005 to about 1.0 mg/ml;
said stabilizing agent is at a concentration of about 0.005 to about 20%; and
said surfactant is at a concentration of about 0.001% to about 1.0%.
